Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Literature DB >> 6577434

Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Abstract

Monoclonal antibody 9.2.27 (mAb 9.2.27) directed to a chondroitin sulfate proteoglycan on human melanoma cells was able to suppress tumor growth in athymic (nu/nu) mice more effectively when bound with polyethylene glycol to murine effector cells than when injected alone. These "armed" effector cells also proved more effective than the monoclonal antibody in eliciting antibody-dependent cellular cytotoxicity against human melanoma target cells in vitro.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1983 PMID： 6577434 PMCID： PMC384265 DOI： 10.1073/pnas.80.17.5407

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

23 in total

1. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas.

Authors: M Lieber; J Mazzetta; W Nelson-Rees; M Kaplan; G Todaro
Journal: Int J Cancer Date: 1975-05-15 Impact factor: 7.396

2. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors: P L Ey; S J Prowse; C R Jenkin
Journal: Immunochemistry Date: 1978-07

3. Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors: D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal: Surgery Date: 1968-07 Impact factor: 3.982

4. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein.

Authors: A C Morgan; D R Galloway; R A Reisfeld
Journal: Hybridoma Date: 1981

5. Antibody-dependent cell-mediated cytolysis (ADCC) with antibody-coated effectors: new methods for enhancing antibody binding and cytolysis.

Authors: J F Jones; D M Segal
Journal: J Immunol Date: 1980-08 Impact factor: 5.422

6. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.

Authors: D O Chee; A W Boddie; J A Roth; E C Holmes; D L Morton
Journal: Cancer Res Date: 1976-04 Impact factor: 12.701

7. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors: H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal: Lancet Date: 1982-04-03 Impact factor: 79.321

8. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma.

Authors: D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal: Eur J Immunol Date: 1979-08 Impact factor: 5.532

9. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.

Authors: F C Giuliani; N O Kaplan
Journal: Cancer Res Date: 1980-12 Impact factor: 12.701

Review 10. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors: J Ritz; S F Schlossman
Journal: Blood Date: 1982-01 Impact factor: 22.113

16 in total

1. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors: Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal: Neoplasia Date: 2010-10 Impact factor: 5.715

2. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors: S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal: Clin Exp Immunol Date: 2008-09 Impact factor: 4.330

3. Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas.

Authors: K Bosslet; H D Mennel; F Rodden; B L Bauer; F Wagner; A Altmannsberger; H H Sedlacek; H Wiegandt
Journal: Cancer Immunol Immunother Date: 1989 Impact factor: 6.968

4. A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.

Authors: K Bosslet; H F Kern; E J Kanzy; A Steinstraesser; A Schwarz; G Lüben; H U Schorlemmer; H H Sedlacek
Journal: Cancer Immunol Immunother Date: 1986 Impact factor: 6.968

5. Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors: A Eisenthal; S A Rosenberg
Journal: Clin Exp Metastasis Date: 1988 Sep-Oct Impact factor: 5.150

6. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing.

Authors: Ludger Grosse-Hovest; Sigrid Müller; Rosa Minoia; Eckhard Wolf; Valeri Zakhartchenko; Hendrik Wenigerkind; Caroline Lassnig; Urban Besenfelder; Mathias Müller; Simon D Lytton; Gundram Jung; Gottfried Brem
Journal: Proc Natl Acad Sci U S A Date: 2004-04-22 Impact factor: 11.205

10. Antibody-dependent cell-mediated cytotoxicity using a murine monoclonal antibody against human colorectal cancer in cancer patients.

Authors: K Takamuku; T Akiyoshi; H Tsuji
Journal: Cancer Immunol Immunother Date: 1987 Impact factor: 6.968